Abstract: The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases having cedrol or a pharmaceutically acceptable salt thereof as an active ingredient. Particularly, the cedrol or the derivative thereof of the present invention inhibits the expression of IL-17A, and in particular, cedrol, cedryl acetate, and cedrene exhibit the effect of delaying the outbreak of psoriasis and treating thereof in a psoriasis animal model. Therefore, these compounds can be used for the treatment of autoimmune diseases mediated by IL-17.

Abstract: In the present invention, a method of inhibiting fatty liver disease is disclosed. The method comprises administrating an effective amount of an extract of Angelica acutiloba Kitagawa to a subject in need thereof at a dosage of 150 to 600 mg for per kilogram per day of the subject in need, lasting for 4 weeks. The extract of Angelica acutiloba Kitagawa is obtained by extracting roots of Angelica acutiloba Kitagawa through a process of supercritical fluid extraction, water extraction, or organic solvent extraction. A preparation method of the extract of Angelica acutiloba Kitagawa is also disclosed in the present invention.

Abstract: The invention generally relates to environmental friendly pesticide compounds, formulations, methods of preparation and application and utilities thereof. More particularly, the invention relates to pesticide compounds and formulations that include terpenes or terpenoids having chemical formula of (C5H8)n, and its derivatives and analogs thereof, as active insecticidal ingredients; certain botanical essential oils as synergists, and other select ingredients as additives.

Abstract: The present invention is directed to a compound of the formula (2) and its uses thereof: wherein T, U, V and W is CR1; R1 is H; X, is CR2 and N with the proviso that at least one X is equal to CR2 and at least one R2 from CR2 is equal to Z; and n and m are 0, 1, 2, 3 to 4 and either n is at least 3 or m is at least 3.

Abstract: Disclosed are compositions comprising beta-caryophyllene (BCP) for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using BCP. Disclosed are also compositions comprising CB2 receptor agonists for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using CB2 receptor agonists.

Abstract: The present invention relates to the use of sesquiterpenes and derivatives thereof as components of animal feed or feed additives for the improvement of animal performance as well as to the corresponding animal feed or feed additives containing them.

Abstract: Described herein are methods of predicting the risk of developing ovarian cancer recurrence of a subject comprising the steps of detecting the expression levels of at least four of the six genes selected from the group consisting of AKT2, KRAS, RAC1, CALM3, RPS6KA2 and YWHAB or the gene products thereof, wherein the presence of increased expression levels of the genes or the gene products is predictive of the increased risk of developing ovarian cancer recurrence in the subject. Kits for practicing the methods are also disclosed.

Abstract: Novel Uses of small molecules, particularly, triterpenoids and ingol diterpenes isolated from Euphorbia neriifolia, are disclosed herein. The triterpenoids are useful as lead compounds for manufacturing a medicament or a pharmaceutical composition for treating cancer; whereas the ingol diterpenes are useful as lead compounds for manufacturing a medicament or a pharmaceutical composition for treating thrombocytopenia.

Abstract: Methods of using extracts of Melicope to impart anti-lipid benefits to skin and/or improve skin conditions resulting from an over-production of lipids.

Abstract: The invention relates to novel medicament formulations containing, as active ingredients, alkylphosphocholines and the like, alkyl-alkanediol-phosphocholines and the like, and (ether)lysolecithins and the like, in different forms of embodiment. The active ingredients are integral constituents of liposomes, also containing cholesterol and the like and a negative charge carrier. The medicament formulations are especially suitable for the treatment and/or prophylaxis of cancer, protozoan diseases such as leishmaniasis and amoebic diseases, acariasis and diseases caused by arthropods, and bacterial diseases, such as ehrlichiosis. Ocular diseases accompanied by uncontrolled cellular processes can also be advantageously influenced.

Abstract: This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.

Abstract: The increasing use of nanotechnology in consumer products and medical applications underlies the importance of understanding its potential toxic effects to people and the environment. Herein are described methods and assays to predict and evaluate the cellular effects of nanomaterial exposure. Exposing cells to nanomaterials at cytotoxic doses induces cell cycle arrest and increases apoptosis/necrosis, activates genes involved in cellular transport, metabolism, cell cycle regulation, and stress response. Certain nanomaterials induce genes indicative of a strong immune and inflammatory response within skin fibroblasts. Furthermore, the described multiwall carbon nanoonions (MWCNOs) can be used as a therapeutic in the treatment of cancer due to its cytotoxicity.

Abstract: Methods of enhancing the appearance of a mammal's hair/fur are provided by the administration of an oral nutraceutical or food composition comprising steviol or a steviol precursor, without chromene, for a time sufficient and in an amount effective to enhance the overall appearance of the mammal's hair/fur. The enhancement of the appearance of the mammal's hair/fur includes restoring hair/fur color, lessening hair loss, increasing the thickness of hair, counteracting age-associated hair thinning, and delaying the onset or severity of age-associated hair loss and thinning. A nutraceutical or food which includes steviol or a steviol precursor in an amount sufficient to enhance the overall appearance of a mammal's hair/fur is also provided.

Abstract: Disinfecting method for disinfecting a room or a surface, comprising the steps of: a) providing a fluid comprising at least one organic compound obtainable from natural substances, wherein the organic compound is provided in an non-polar or polar medium, or in a mixture of non-polar and polar media; b) mixing the fluid with a gas such that fluid particles are suspended in the gas, and an aerosol of fluid particles is formed; c) directing a flow of the aerosol formed in step b) on said surface or into said room.

Abstract: The invention relates to a method of use, of a mixture of chemical compounds for a shark repellent, as well as methods of protection garments in using such material(s). Generally, there are not many shark repellents. This shark repellent contains a mixture of chemical compounds that are highly toxic and trenchant, which will deter the shark from injured or non-injured humans or animals, once the mixture is immersed in water.

Abstract: Substituted benzamide compounds corresponding to formula (I) in which R5, R6, R7, R8, a, b, c, d, t, D and X have defined meanings, a process for their preparation, pharmaceutical compositions comprising such compounds, and a method of using such compounds to treat pain and other conditions mediated at least in part via the bradykinin 1 receptor.

Abstract: The invention provides compositions and methods for inducing apoptosis in a cancer cell or a cell transformed by Epstein-Barr virus (EBV). Specifically, the invention provides Beta-Caryophyllene or a composition thereof to induce apoptosis. The invention further provides treating lymphoma or Epstein-Barr virus (EBV) associated disease in a subject by administering Beta-Caryophyllene or a composition thereof.

Abstract: Compositions and methods for administering memantine to a subject are provided. In particular, a solid pharmaceutical composition in a unit dosage form for once daily oral administration is provided. The compositions comprises an extended release formulation of 22.5 mg to 33.75 mg memantine, or a pharmaceutically acceptable salt thereof, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by a change in memantine concentration as a function of time (dC/dT) that is less than 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0 hours to 6 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. Methods of treating dementia, in particular Alzheimer's diseases, using the compositions are provided.

Abstract: The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.

Abstract: The present invention provides compositions and methods for treating, inhibiting or preventing the developing of a plant pathogenic disease. The compositions comprise volatile organic compounds effective to inhibit the growth of, or kill pathogenic microbes, including Ganoderma boninense. Invention compositions are especially useful in preventing and treating basal stem rot in the oil palm, and can be applied in the vicinity of the plant or used to sterilize the plant growth medium prior to or concurrent with plant growth therein.

Abstract: The present invention comprises compositions, methods and cell lines related to controlling insects. An embodiment of a composition comprises a plant essential oil and targets at least one receptor of insects chosen from tyramine receptor, Or83b olfactory receptor, and Or43a olfactory receptor, resulting in a change in the intracellular levels of cAMP, Ca2+, or both in the insects.

Abstract: The invention concerns compositions comprising substituted 1,3-diphenylprop-2-en-1-one derivatives designed for therapeutic use. The inventive compositions are useful in particular for preventing or treating cardiovascular diseases, syndrome X, Ia restenosis, diabetes, obesity, hypertension, inflammatory diseases, cancers or neoplasms (benign or malignant tumors), neurodegenerative, dermatological diseases and disorders related to oxidative stress, for preventing or treating the effects of ageing in general and for example skin ageing, in particular in the field of cosmetics (occurrence of wrinkles and the like).

Abstract: Insecticidal compositions have at least one active agent and at least one insecticide. The active agent can include perilla oil, a component found in perilla oil, or a perillaldehyde or carvone analog. The insecticide can include a pyrethrum, pyrethrin, pyrethroid, neonicotinoid, chlofenapyr, ethiprole, sulfoxoflor, carbamate, organophosphate, or organochlorine. Methods for controlling insects include contacting an insect with an effective amount of a composition described in this specification. Modified plants that produce an active agent can be contacted with an insecticide.

Abstract: The invention provides methods for administering memantine to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt is administered to a patient suffering from a neurological condition, such as Alzheimer's disease, Parkinson's disease or dementia. The extended release form achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.

Abstract: The invention relates to therapeutic agents for use in the prevention or treatment of Alzheimer's disease. In particular the invention relates to use of inhibitors of cell cycle re-entry and progression to the G1/S transition or inhibitors of progression of the cell cycle through the G1/S transition point in the prevention or treatment of Alzheimer's disease.

Abstract: The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.

Abstract: The invention provides methods for administering extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil is administered to a patient suffering from a neurological condition, such as Alzheimer's disease, Parkinson's disease or dementia. The extended release form of memantine achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.

Abstract: The invention provides compostions for administering memantine to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.

Abstract: The present invention relates to desferoxamine conjugates, derivatives and analogues thereof. In particular, the present invention relates to desferoxamine conjugates, analogues and derivatives thereof, and methods for reducing levels of metals, especially iron, in a mammal. Uses of the compounds according to the invention are also provided. Compounds of the present invention may also be used to treat iron dyshomeostasis disorders, cancer, malaria and fungal infections. The compounds of the invention may be formulated into a pharmaceutical composition or packaged into kits.

Abstract: The invention provides a method for controlling Huanglongbing (HLB) disease of citrus plants through expressing genes encoding synthases for sesquiterpenes such as ?-caryophyllene, and ?-copaene, and combinations thereof, in citrus plants. Methods of controlling HLB comprising applying at least one purified sesquiterpene, which repels Diaphorina citri and/or Tryoza erytrae psyllid insects, so as to control the HLB disease of citrus plants, are also disclosed.

Abstract: A process for the hydrogenation of a mixture of caryophyllenes by contact with hydrogen in the presence of a supported catalyst. The resulting products are useful for the application to skin.

Abstract: The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.

Abstract: cis-Jasmone has been discovered to be useful as a semiochemical that changes the behavior of insects and/or the physiology of plants. It has direct signalling roles with plant-feeding aphids, in attraction of aphid predators and parasitoids, and may act as an airborne signal inducing production of volatile plant semiochemicals, including the monoterpene (E)-?-ocimene, that stimulate foraging by parasitoids. It is an extremely benign compound having, to human beings, a pleasant aroma and gives a long-lasting effect after removal of the stimulus.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hyperlipidemia, fatty liver, diabetes and obesity comprising a sesquiterpene derivative as an active ingredient. The sesquiterpene derivatives of the present invention leads to decrease in body fat weight, visceral fat weight and total cholesterol levels, triglyceride of plasma and liver tissue, blood glucose and blood insulin levels in a fast state, finally exhibiting efficacies on prevention or treatment of hyperlipidemia, fatty liver, diabetes and obesity.

Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.

Abstract: A method includes positioning an effective amount of a thermal target material at a treatment site of a patient. The treatment site, that is, the location of the thermal target material, comprises a location adjacent to biological tissue to be treated. The thermal target material includes carbon molecules preferably in a carrier fluid. Regardless of the particular structure of the carbon, the carbon molecules in the material heat very rapidly in response to incident microwave radiation and radiate heat energy. The heat energy radiated from an effective amount of the thermal target material when subjected to an effective quantity of microwave energy causes localized heating around the thermal target material. This localized heating may be applied for therapeutic purposes. However, the microwave radiation necessary to produce therapeutically effective heating is insufficient to cause cellular damage in the biological tissue by direct absorption in the tissue.

Abstract: Disclosed is a composition including camphene as an active ingredient for preventing or treating obesity, dyslipidemia, fatty liver or insulin resistance syndrome. The composition of the present disclosure including camphene as an active ingredient suppresses differentiation of adipocytes, reduces body fat, reduces visceral fat, reduces total cholesterol level, reduces serum triglyceride level and reduces liver tissue triglyceride level, and thus exhibits preventive or therapeutic activity for obesity, hyperlipidemia or fatty liver. Furthermore, the composition of the present disclosure exhibits the effect of improving type 2 diabetes or insulin resistance and related metabolic disease by significantly reducing fasting blood sugar level and blood insulin level.

Abstract: The invention concerns compositions comprising substituted 1,3-diphenylprop-2-en-1-one derivatives designed for therapeutic use. The inventive compositions are useful in particular for preventing or treating cardiovascular diseases, syndrome X, Ia restenosis, diabetes, obesity, hypertension, inflammatory diseases, cancers or neoplasms (benign or malignant tumors), neurodegenerative, dermatological diseases and disorders related to oxidative stress, for preventing or treating the effects of ageing in general and for example skin ageing, in particular in the field of cosmetics (occurrence of wrinkles and the like).

Abstract: Use of an anti-inflammatory agent such as povidone iodine for the preparation of a pharmaceutical composition for the treatment of diseases of the lower respiratory tract which are susceptible to the administration of such agents.

Abstract: The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.

Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.

Abstract: The present invention comprises compositions, methods and cell lines related to controlling insects. An embodiment of a composition comprises a plant essential oil and targets at least one receptor of insects chosen from tyramine receptor, Or83b olfactory receptor, and Or43a olfactory receptor, resulting in a change in the intracellular levels of cAMP, Ca2+, or both in the insects.

Abstract: Methods and compositions are provided for treating a urinary tract infection (UTI). The methods involve administering to a subject in need thereof a cAMP elevator or agent that mimics cAMP, particularly a labdane diterpene such as forskolin or a derivative or analog thereof in a therapeutically effective amount to treat a UTI. The methods may further include administration of at least one cAMP elevator in combination with one or more additional active compounds from other classes of therapeutic agents, such as antimicrobial agents or cholesterol lowering drugs. Compositions of the invention include pharmaceutical compositions and kits for treating a UTI in a subject in need thereof that include therapeutically effective amounts of at least two cAMP elevators, particularly where one of the cAMP elevators is a labdane diterpene such as forskolin or a derivative or analog thereof.

Abstract: A pharmaceutical composition for 1) increasing weight gain; and/or 2) decreasing weight loss; and/or 3) increasing appetite in a subject in need thereof, comprising purified ?-caryophyllene together with a pharmaceutically acceptable carrier. Also provided are pharmaceutical compositions for use in the prevention or treatment of Anorexia-Cachexia Syndrome, the pharmaceutical composition comprising purified ?-caryophyllene together with a pharmaceutically acceptable carrier.

Abstract: The present invention relates to heterocyclic inhibitors of stratum corneum chymotryptic enzyme (SCCE). More particularly, the invention relates to the use of compounds with the formula (I) or (II) for treatment of certain diseases, in particular skin diseases such as pruritus, as well as cancer such as ovarian cancer.

Abstract: A pharmaceutical composition comprising a water insoluble sesquiterpene, one or more antioxidants and one or more solubilizers selected from the group consisting of an oil, PEG400, a derivative of castor oil and ethylene oxide, and polysorbate 80, and methods of use thereof.

Abstract: Functional ingredients including an esterified component and microencapsulated in an enteric matrix to increase the microencapsulation efficiency and reduce undesired organoleptic properties of the microencapsulated material while providing a desired release rate and ester hydrolysis rate, the process including forming an emulsion in water and titrating the emulsion with a precipitating agent to produce a particulate precipitate.

Abstract: cis-Jasmone has been discovered to be useful as a semiochemical that changes the behavior of insects and/or the physiology of plants. It has direct signalling roles with plant-feeding aphids, in attraction of aphid predators and parasitoids, and may act as an airborne signal inducing production of volatile plant semiochemicals, including the monoterpene (E)-?-ocimene, that stimulate foraging by parasitoids. It is an extremely benign compound having, to human beings, a pleasant aroma and gives a long-lasting effect after removal of the stimulus.

Abstract: The present invention relates to the use of sesquiterpenes and derivatives thereof as components of animal feed or feed additives for the improvement of animal performance as well as to the corresponding animal feed or feed additives containing them.

Abstract: Methods for repelling flying or biting insects from an area, a human, or an animal subject are provided. The methods include treating the area, or applying to a subject or to a device worn by the subject seychellene, ?-guaiene, and ?-bulnesene, or a mixture thereof. Additional compounds including ?-caryophyllene, isocaryophyllene, ?-caryophyllene oxide, ?-caryophyllene ketone, ?-humulene, ?-patchoulene, ?-patchoulene, ?-elemene, (+)-longipinene, (?)-isolongifolene, (+)-longifolene, and linalool, clove oil, and/or patchouli oil may also be used.